Chen Huimin, Zhang Zhiping, Chen Xiaojuan, Wang Chaoyu, Chen Mingdi, Liao Huizhao, Zhu Jinru, Zheng Zhenzhen, Chen Riken
The Second Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China.
The People's Hospital of JiangMen, Jiangmen Hospital, Southern Medical University, Jiangmen, China.
Front Pharmacol. 2023 Dec 12;14:1089847. doi: 10.3389/fphar.2023.1089847. eCollection 2023.
A meta-analysis is conducted to evaluate the effectiveness and safety of bevacizumab in hereditary hemorrhagic telangiectasia (HHT) epistaxis. Two researchers search PubMed, EMBASE and Web of Science databases from their inception until September 3th, 2023. The literature is read and screened, and valid data extracted, collated and analyzed. Its quality is then assessed using the Cochrane risk assessment scale. This study uses Endnote 9.3 software for literature management and RevMan 5.3.1 software for evaluation. A total of 7 documents met the requirements, including a total of 359 patients, and the literature quality evaluation was grade B. The Meta-analysis results showed that:Bevacizumab reduces the Epistaxis Severity Score (ESS) in patients with HHT epistaxis compared with the control [WMD = -0.22,95%CI (-0.38, -0.05), = 0.01]. However, there is no significant effect on duration of epistaxis [WMD = -15.59, 95%CI (-70.41,39.23), = 0.58] and number of epistaxes [WMD = -1.27,95%CI (-10.23,7.70), = 0.78] in patients with HHT epistaxis. In terms of adverse effects, there is no significant difference between the bevacizumab group and control group [OR = 1.36, 95% CI (0.54, 3.44), = 0.52]. Bevacizumab is superior to the control group in the treatment of HHT epistaxis, and adverse reactions are not further increased in the bevacizumab group than in the control group, suggesting that bevacizumab has clinical value in the treatment of HHT epistaxis.
进行一项荟萃分析以评估贝伐单抗治疗遗传性出血性毛细血管扩张症（HHT）鼻出血的有效性和安全性。两名研究人员检索了PubMed、EMBASE和Web of Science数据库，检索时间从数据库建立至2023年9月3日。阅读并筛选文献，提取、整理和分析有效数据。然后使用Cochrane风险评估量表评估其质量。本研究使用Endnote 9.3软件进行文献管理，使用RevMan 5.3.1软件进行评估。共有7篇文献符合要求，共纳入359例患者，文献质量评价为B级。荟萃分析结果显示：与对照组相比，贝伐单抗可降低HHT鼻出血患者的鼻出血严重程度评分（ESS）[加权均数差（WMD）=-0.22，95%置信区间（CI）（-0.38，-0.05），P=0.01]。然而，对于HHT鼻出血患者的鼻出血持续时间[WMD=-15.59，95%CI（-70.41，39.23），P=0.58]和鼻出血次数[WMD=-1.27，95%CI（-10.23，7.70），P=0.78]，贝伐单抗没有显著影响。在不良反应方面，贝伐单抗组与对照组之间无显著差异[比值比（OR）=1.36，95%CI（0.54，3.44），P=0.52]。贝伐单抗在治疗HHT鼻出血方面优于对照组，且贝伐单抗组的不良反应没有比对照组进一步增加，这表明贝伐单抗在治疗HHT鼻出血方面具有临床价值。
Zotero 插件
